Lactate Dehydrogenase Isoenzymes 1 and 5: Differential Expression by Neoplastic and Stromal Cells in Non-Small Cell Lung Cancer and Other Epithelial Malignant Tumors

Tumor Biology ◽  
2003 ◽  
Vol 24 (4) ◽  
pp. 199-202 ◽  
Author(s):  
Michael I. Koukourakis ◽  
Alexandra Giatromanolaki ◽  
Efthimios Sivridis
Keyword(s):  
Lung Cancer ◽  
Lactate Dehydrogenase ◽  
Small Cell Lung Cancer ◽  
Differential Expression ◽  
Cell Lung Cancer ◽  
Stromal Cells ◽  
Malignant Tumors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lactate Dehydrogenase Isoenzymes

scholarly journals Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus

2007 ◽  
Vol 60 (6) ◽  
pp. 608-614 ◽  
Author(s):  
M C Boelens ◽  
A van den Berg ◽  
I Vogelzang ◽  
J Wesseling ◽  
D S Postma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Differential Expression ◽  
Adhesion Molecules ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Immunotherapy for Advanced Small Cell Lung Cancer: A Case Report

2021 ◽  
Vol 6 (5) ◽  
Author(s):  
Wang J ◽  
Deng C ◽  
Zhu X ◽  
Zou X ◽  
Wang J
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Malignant Tumors ◽  
Small Cell ◽  
Immune Checkpoints ◽  
Small Cell Lung ◽  
Advanced Stages ◽  
Made In

In recent years, extraordinary achievements have been made in treating tumor immune checkpoints as targets, which significantly contributes to the research and development of novel immunologic drugs and their application in treating malignant tumors. However, few immunologic drugs can be administered to treat Small Cell Lung Cancer (SCLC). Currently, the focus of most clinical studies is placed on treating SCLC with a combination of immunotherapy and chemotherapy, which is relatively expensive and not covered by medical insurance, thus imposing a heavy economic burden on patients. Meanwhile, obvious adverse reactions occur during chemotherapy, which is still unacceptable to many patients and hence has not yet been widely adopted in clinical practice. Therefore, whether immunotherapy alone can help patients with SCLC, improve their quality of life, and prolong their survival time is a topic we will study in the future. In this case, an attempt was made to apply camrelizumab, an immunologic drug, in the treatment of SCLC in advanced stages, and a favorable efficacy was achieved.

The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.

1991 ◽  
Vol 9 (6) ◽  
pp. 954-961 ◽  
Author(s):  
U Sagman ◽  
R Feld ◽  
W K Evans ◽  
D Warr ◽  
F A Shepherd ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lactate Dehydrogenase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Serum Lactate ◽  
Small Cell ◽  
Serum Lactate Dehydrogenase ◽  
Small Cell Lung ◽  
Normal Range ◽  
Pretreatment Serum

Pretreatment serum lactate dehydrogenase (LDH) levels were assayed in 288 patients presenting with small-cell lung cancer (SCLC) between 1976 and 1985. Patients were routinely staged by physical examination, chest x-ray, bone, brain, and liver scans, and bone marrow evaluation. Clinical response and survival were assessed following treatment with combination chemotherapy as part of four clinical trials. Patients with extensive disease (ED) presented with a higher incidence (108 of 147, 73%) of abnormally elevated LDH (greater than 193 IU/L) than those (65 of 141, 46%) with limited disease (LD) (P = 2 x 10(-6)). Forty percent of patients had an initial normal LDH level and a higher response rate (89 of 108, 82%; complete response [CR], 47%) than those with elevated values of LDH (119 of 156, 76%; CR, 29%). The CR rate varied inversely with the level of LDH in patients with LD (P = .026) but not in those with ED (P = .300). The median survival time and 1-year and 2-year survival rates for patients with elevated LDH were 39 weeks and 33% and 6%, respectively, whereas for those with a normal LDH level these were 53 weeks and 54% and 16%, respectively. Patients with LD and elevated levels of LDH manifested a higher relative death rate (1.63:1) when compared with patients with LD and LDH in the normal range (P = .0083). The survival of patients with ED did not differ between those with normal and elevated levels of LDH (P = .273). A significant survival advantage persisted for patients with LDH in the normal range following adjustments for extent of disease, performance status (PS), and treatment protocol (P = .044, log-rank analysis). In conclusion, serum LDH appears to be a significant independent pretreatment prognostic factor in patients with SCLC that correlates with stage of disease, response to treatment, and survival.

scholarly journals Lactate-Dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1

2010 ◽  
Vol 5 (1) ◽  
Author(s):  
Gian Kayser ◽  
Ahmad Kassem ◽  
Wulf Sienel ◽  
Luzie Schulte-Uentrop ◽  
Dominik Mattern ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lactate Dehydrogenase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document